News
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director.
.jpeg)
Why working with a university isn't always best for DTx start-ups
Our Co-Founder Michael explores the best options for DTx startups looking to start generating clinical evidence and why it might not always be best to work with academic institutions.
Why I Joined Lindus Health - Emma Ogburn PhD, VP Clinical Operations
To work on innovative trials and accelerate access to treatments. To tackle disparities in research accessibility. To use technology to accelerate studies and work with a motivated team. Hear more from our VP of Clinical Operations, Emma Ogburn PhD, on why she joined Lindus Health.
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director.
.png)
Dr. Paul Billings Joins Lindus Health's Scientific Advisory Board
Lindus Health has announced the appointment of Dr. Paul Billings to its Scientific Advisory Board, strengthening its expertise in diagnostic and genomic medicine. A recognized leader in diagnostics with decades of experience across industry and clinical research, Dr. Billings will help guide Lindus Health’s strategy for designing and executing high-quality diagnostic clinical trials, supporting faster, more reliable paths from diagnostic innovation to patient impact.
Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials
This collaboration is essential to eliminating traditional barriers in patient recruitment and reducing friction when transitioning between development stages and CRO partners, ultimately accelerating the delivery of breakthrough treatments to patients.
Lindus Health Named Rising Star in the 2025 Deloitte Technology Fast 50
This prestigious recognition reflects Lindus’ ongoing commitment to developing adaptive, innovative technology that fixes the broken Contract Research Organization (CRO) model through its all-in-one solution.
All-in-One CRO Solution Lindus Health Welcomes Heather Davis as Vice President of US Clinical Operations
Heather Davis joins the executive team, bringing 30 years of experience to continue expanding Lindus Health's footprint in North America.
Lindus Health Partners with Yendou to Streamline Site Engagement and Accelerate Clinical Trial Feasibility
This collaboration strengthens Lindus’ ability to deliver robust end-to-end clinical trials through one unified solution.
Lindus Health and Frieda Health Successfully Complete Clinical Trial Evaluating Novel Treatment for Menopause Symptoms
This open-label pilot study evaluated the Frieda Menova app—Frieda Health's proprietary digital therapeutic that integrates cognitive behavioral therapy (CBT)—for its effectiveness in alleviating menopausal symptoms, including vasomotor disturbances, sleep disruption, and psychological distress.
New Study from Lindus Health Finds Nearly Half of Consumers Will Abandon Health Products Lacking Clear Scientific Evidence
Discover consumer purchasing motivations from Lindus Health's latest market research.